Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients

Lingjun Zhang, Yan Li, John Payne, Sunil Srivastava, Xingjun Fan, John Fung, Xiaorong Li, Timothy S. Kern, Feng Lin

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The loss of retinal pericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying RPC death is unclear. Although it was postulated in previous studies using bovine RPCs that autoantibodies against RPCs might develop and induce RPC death, it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whether such autoantibodies contribute to RPC damage/loss, and if they do, through which mechanism. We screened serum samples from DR patients and controls using primary human RPCs and found that that levels of IgGs reactive to RPCs were significantly higher in the DR group than the control group. Serum samples with higher RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC-reactive IgG levels. We also assessed levels of the complement-activation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5a, but not C4a, were higher in the DR group than control group. These data provide evidence the first time showing that autoantibodies against RPCs can develop in DR patients, and that these autoantibodies could contribute to pericyte damage through complement activation.

Original languageEnglish (US)
Article number20341
JournalScientific Reports
Volume6
DOIs
StatePublished - Feb 3 2016
Externally publishedYes

Fingerprint

Pericytes
Diabetic Retinopathy
Autoantibodies
Complement Activation
Serum
Immunoglobulin G
Control Groups
Surface Antigens

ASJC Scopus subject areas

  • General

Cite this

Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients. / Zhang, Lingjun; Li, Yan; Payne, John; Srivastava, Sunil; Fan, Xingjun; Fung, John; Li, Xiaorong; Kern, Timothy S.; Lin, Feng.

In: Scientific Reports, Vol. 6, 20341, 03.02.2016.

Research output: Contribution to journalArticle

Zhang, L, Li, Y, Payne, J, Srivastava, S, Fan, X, Fung, J, Li, X, Kern, TS & Lin, F 2016, 'Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients', Scientific Reports, vol. 6, 20341. https://doi.org/10.1038/srep20341
Zhang, Lingjun ; Li, Yan ; Payne, John ; Srivastava, Sunil ; Fan, Xingjun ; Fung, John ; Li, Xiaorong ; Kern, Timothy S. ; Lin, Feng. / Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients. In: Scientific Reports. 2016 ; Vol. 6.
@article{e30ed4ea567e46aeaf9f40a9ce420c8a,
title = "Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients",
abstract = "The loss of retinal pericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying RPC death is unclear. Although it was postulated in previous studies using bovine RPCs that autoantibodies against RPCs might develop and induce RPC death, it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whether such autoantibodies contribute to RPC damage/loss, and if they do, through which mechanism. We screened serum samples from DR patients and controls using primary human RPCs and found that that levels of IgGs reactive to RPCs were significantly higher in the DR group than the control group. Serum samples with higher RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC-reactive IgG levels. We also assessed levels of the complement-activation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5a, but not C4a, were higher in the DR group than control group. These data provide evidence the first time showing that autoantibodies against RPCs can develop in DR patients, and that these autoantibodies could contribute to pericyte damage through complement activation.",
author = "Lingjun Zhang and Yan Li and John Payne and Sunil Srivastava and Xingjun Fan and John Fung and Xiaorong Li and Kern, {Timothy S.} and Feng Lin",
year = "2016",
month = "2",
day = "3",
doi = "10.1038/srep20341",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients

AU - Zhang, Lingjun

AU - Li, Yan

AU - Payne, John

AU - Srivastava, Sunil

AU - Fan, Xingjun

AU - Fung, John

AU - Li, Xiaorong

AU - Kern, Timothy S.

AU - Lin, Feng

PY - 2016/2/3

Y1 - 2016/2/3

N2 - The loss of retinal pericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying RPC death is unclear. Although it was postulated in previous studies using bovine RPCs that autoantibodies against RPCs might develop and induce RPC death, it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whether such autoantibodies contribute to RPC damage/loss, and if they do, through which mechanism. We screened serum samples from DR patients and controls using primary human RPCs and found that that levels of IgGs reactive to RPCs were significantly higher in the DR group than the control group. Serum samples with higher RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC-reactive IgG levels. We also assessed levels of the complement-activation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5a, but not C4a, were higher in the DR group than control group. These data provide evidence the first time showing that autoantibodies against RPCs can develop in DR patients, and that these autoantibodies could contribute to pericyte damage through complement activation.

AB - The loss of retinal pericytes (RPCs) is a hallmark of early stage diabetic retinopathy (DR), but the mechanism underlying RPC death is unclear. Although it was postulated in previous studies using bovine RPCs that autoantibodies against RPCs might develop and induce RPC death, it is unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whether such autoantibodies contribute to RPC damage/loss, and if they do, through which mechanism. We screened serum samples from DR patients and controls using primary human RPCs and found that that levels of IgGs reactive to RPCs were significantly higher in the DR group than the control group. Serum samples with higher RPC-reactive IgG levels induced more severe complement-mediated RPC damage than those with lower RPC-reactive IgG levels. We also assessed levels of the complement-activation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5a, but not C4a, were higher in the DR group than control group. These data provide evidence the first time showing that autoantibodies against RPCs can develop in DR patients, and that these autoantibodies could contribute to pericyte damage through complement activation.

UR - http://www.scopus.com/inward/record.url?scp=84957837449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957837449&partnerID=8YFLogxK

U2 - 10.1038/srep20341

DO - 10.1038/srep20341

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 20341

ER -